Department of Ophthalmology, University of Yüzüncü Yil, Van, Turkey.
Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):513-20. doi: 10.1007/s00417-010-1551-2. Epub 2010 Nov 4.
To report the long-term effect of intravitreal bevacizumab on serous macular detachment (SMD) in central retinal vein occlusion (CRVO).
Retrospective, interventional, noncomparative case series. Nineteen consecutive patients (19 eyes) with SMD secondary to CRVO were included. Primary outcomes were the change of the best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) at final visit. Secondary outcome was the resolution of the SMD.
The mean patient age was 65.6 years, and the mean follow-up time 21.6 months. Of the 19 eyes, 15 eyes were non-ischemic. The average number of bevacizumab injections was 5.9 from baseline to the final visit. Mean logMAR BCVA improved from 1.20 ± 0.45 (20/317) to [Formula: see text] and mean CFT decreased from 918 ± 280 μm to [Formula: see text] at the final visit. The SMD resolved in 16 of the 19 eyes completely. No local or systemic complication was observed.
In this retrospective case series, a significant improvement of the vision and resolution of the SMD was found after bevacizumab treatment for CRVO with SMD. Large case series are necessary to evaluate the role of the intravitreal bevacizumab treatment for CRVO associated with SMD.
报告玻璃体内注射贝伐单抗治疗视网膜中央静脉阻塞（CRVO）伴浆液性黄斑视网膜脱离（SMD）的长期疗效。
回顾性、干预性、非对照病例系列研究。纳入 19 例（19 只眼）CRVO 继发 SMD 患者。主要结局是最终随访时最佳矫正视力（BCVA）和中心视网膜厚度（CFT）的变化。次要结局是 SMD 的消退。
患者平均年龄 65.6 岁，平均随访时间 21.6 个月。19 只眼中，15 只为非缺血型。从基线到最终随访，贝伐单抗注射的平均次数为 5.9 次。平均 logMAR BCVA 从 1.20 ± 0.45（20/317）提高至[Formula: see text]，平均 CFT 从 918 ± 280 μm 降至[Formula: see text]。19 只眼中的 16 只完全消退了 SMD。未观察到局部或全身并发症。
在本回顾性病例系列研究中，CRVO 伴 SMD 患者接受贝伐单抗治疗后，视力显著改善，SMD 消退。需要更大的病例系列来评估玻璃体内注射贝伐单抗治疗与 SMD 相关的 CRVO 的作用。
